No Data
No Data
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Zentalis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Zentalis Pharmaceuticals Price Target Cut to $40.00/Share From $46.00 by HC Wainwright & Co.
Zentalis Pharmaceuticals Price Target Cut to $40.00/Share From $46.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Zentalis Pharma, Lowers Price Target to $40
HC Wainwright & Co. analyst Andrew Fein maintains Zentalis Pharma with a Buy and lowers the price target from $46 to $40.
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
Zentalis Pharmaceuticals (ZNTL) has an average outperform rating and a price target range of $15 to $50, according to analysts polled by Capital IQ. Price: 12.06, Change: -0.25, Percent Change: -2.03
Zentalis Pharmaceuticals Is Maintained at Buy by Stifel
Zentalis Pharmaceuticals Is Maintained at Buy by Stifel